GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review additional materials submitted by the company, suggesting the company may ...

GSK's Blenrep Drug Recommended for Approval by European Medicines Agency Provided by Dow Jones May 23, 2025, 12:02:00 PM. By Nina Kienle .

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, ...

With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

Blenrep had previously been approved in the U.S., European Union, U.K., and other countries, but GSK pulled it from the market in 2022 after the drug failed in a study meant to confirm its benefit.

GSK expects peak annual sales for Blenrep, chemically called belantamab mafodotin, of over 3 billion pounds ($3.97 billion). The drug is currently under review for approval in more than 10 countries.